Life Extension Skin Care Sale

Life Extension Magazine

LE Magazine September 2004
image
An Innovative New Treatment for Migraine
By Dr. Sergey A. Dzugan

Summary
Analysis of the medical literature and our own experience convince us that migraine is a complex disorder that comprises malfunctions in several systems: the neurohormonal system, which includes a feedback loop mechanism between the hypothalamus, pituitary gland, and glands that produce steroid hormones; the sympathetic-parasympathetic nervous systems; the calcium-magnesium ion system; the pineal gland; and the digestive system. All these systems and changes within them are closely interrelated, and each can be a trigger mechanism for migraine. Contradictory results with other migraine treatments—for example, using medications that modulate serotonin—offer additional evidence that the problem is not high or low sympathetic nervous system activity, but rather an imbalance between the sympathetic and parasympathetic nervous systems.

Following this logic, the basic method of migraine treatment must be directed toward restoring integrity between these different systems. In our hands, the simultaneous restoration of neurohormonal and metabolic integrity was an effective approach to the successful management of migraine.

References

1. Edmeads J. History of migraine treatment. Can J Clin Pharmacol. 1999;6 Suppl A:5A- 8A.

2. Mathew NT. Pathophysiology, epidemiolgy, and impact of migraine. Clin Cornerstone. 2001;4(3):1-17.

3. Gazerani P, Pourpak Z, Ahmadiani A, Hemmati A, Kazemnejad A. A correlation between migraine, histamine and immunoglobulin e. Scand J Immunol. 2003 Mar;57(3):286-90.

4. Lampl C, Buzath A, Baumhackl U, Klingler D. One-year prevalence of migraine in Austria: a nation-wide survey. Cephalalgia. 2003 May;23(4):280-6.

5. Granella F, Cavallini A, Sandrini G, Manzoni GC, Nappi G. Long-term outcome of migraine. Cephalalgia. 1998 Feb;18 Suppl 21:30-3.

6. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993 Jun;43(6 Suppl 3):S6-10.

7. Rajda C, Tajti J, Komoroczy R, Seres E, Klivenyi P, Vecsei L. Amino acids in the sali- va of patients with migraine. Headache. 1999 Oct;39(9):644-9.

8. Koehler PJ, Isler H. The early use of ergo- tamine in migraine. Edward Woakes’ report of 1868, its theoretical and practical back- ground and its international reception. Cephalalgia. 2002 Oct;22(8):686-91.

9. Allain H, Schuck S, Mauduit N, Saiag B, Pinel JF, Bentue-Ferrer D. The physiopathology of migraine. Pathol Biol (Paris). 2000 Sep;48(7):613-8.

10. Prusinski A. Current views on pathophysiol- ogy of migraine: part I. Genetics of migraine. Genesis of the vascular theory. Neurol Neurochir Pol. 1995 Nov;29(6):845- 55.

11. Pichler M, Linzmayer L, Grunberger J, Wessely P. Stress management in migraine. Wien Klin Wochenschr. 1988 Jun 10;100(12):385-91.

12. Welch KM, Darnley D, Simkins RT. The role of estrogen in migraine: a review and hypothesis. Cephalalgia. 1984 Dec;4(4):227- 36.

13. Guaschino S, Spinillo A, Sances G, Martignoni E. Menstrual migraine, old and new. Clin Exp Obstet Gynecol. 1985;12(3- 4):67-71.

14. McCall RB, Huff R, Chio CL, et al. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU- 142633. Cephalalgia. 2002 Dec;22(10):799- 806.

15. Horrobin DF. Hypothesis: prostaglandins and migraine. Headache. 1977 Jul;17(3):113-7.

16. Vardi Y, Rabey IM, Streifler M, Schwartz A, Lindner HR, Zor U. Migraine attacks. Alleviation by an inhibitor of prostaglandin synthesis and action. Neurology. 1976 May;26(5):447-50.

17. Hanington E. Migraine. A platelet hypothesis. Biomedicine. 1979 Jun;30(2):65-6.

18. Hanington E. Migraine: the platelet hypothesis after 10 years. Biomed Pharmacother. 1989;43(10):719-26.

19. Lance JW. Headache: classification, mecha- nism and principles of therapy, with particular reference to migraine. Recenti Prog Med. 1989 Dec;80(12):673-80.

20. Burnstock G. Pathophysiology of migraine: a new hypothesis. Lancet. 1981 Jun 27;1(8235):1397-9.

21. Olsen TS, Friberg L, Lassen NA. Migraine aura—vascular or neuronal disease? Ugeskr Laeger. 1990 May 21;152(21):1507-9.

22. Skyhoj Olsen T. Migraine with and without aura: the same disease due to cerebral vasospasm of different intenstity. A hypothesis based on CBF studies during migraine. Headache. 1990 Apr;30(5):269-72.

23. Feuerstein M, Bush C, Corbisiero R. Stress and chronic headache: a psychophysiological analysis of mechanisms. J Psychosom Res. 1982;26(2):167-82.

24. Glueck CJ, Bates SR. Migraine in children: association with primary and familial dyslipoproteinemias. Pediatrics. 1986 Mar;77(3):316-21.

25. Welch KM, D’Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin. 1990 Nov;8(4):817- 28.

26. Schoenen J, Bottin D, Hardy F, Gerard P. Cephalic and extracephalic pressure pain thresholds in chronic tension-type headache. Pain. 1991 Nov;47(2):145-9.

27. Spector RH. Migraine. Surv Ophthalmol. 1984 Nov;29(3):193-207.

28. Gobel H, Heinze A, Stolze H, Heinze- Kuhn K, Lindner V. Open-labeled long- term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Cephalalgia. 1999 Sep;19(7):676-83.

29. Rapoport AM. Frovatriptan: pharmacological differences and clinical results. Curr Med Res Opin. 2001;17 Suppl 1:s68-70.

30. Young WB, Hopkins MM, Shechter AL, Silberstein SD. Topiramate: a case series study in migraine prophylaxis. Cephalalgia. 2002 Oct;22(8):659-63.

31. Lake AE 3rd, Saper JR. Chronic headache: New advances in treatment strategies. Neurology. 2002 Sep 10;59(5 Suppl 2):S8- 13.

32. Diamond S. Migraine headache. Its diagno- sis and treatment. Clin J Pain. 1989;5(1):3-9.

33. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. Neurology. 1994 Oct;44(10 Suppl 7):S6-16.

34. Baumel B. Migraine: a pharmacologic review with newer options and delivery modalities. Neurology. 1994 May;44(5 Suppl 3):S13-7.

35. Cady RK. Diagnosis and treatment of migraine. Clin Cornerstone. 1999;1(6):21- 32.

36. Young WB, Silberstein SD, Dayno JM. Migraine treatment. Semin Neurol. 1997;17(4):325-33.

37. Lance JW. Headache. Ann Neurol. 1981 Jul;10(1):1-10.

38. Ferrari MD. Biochemistry of migraine. Pathol Biol (Paris). 1992 Apr;40(4):287-92.

39. Cassidy EM, Tomkins E, Dinan T, Hardiman O, O’Keane V. Central 5-HT receptor hypersensitivity in migraine with- out aura. Cephalalgia. 2003 Feb;23(1):29-34.

40. Selmaj K. Blood serotonin level in sciatica and the serotonin theory of migraine pathogenesis. Neurol Neurochir Pol. 1979 Mar;13(2):169-72.

41. Toglia JU. Melatonin: a significant contributor to the pathogenesis of migraine. Med Hypotheses. 2001 Oct;57(4):432-4.

42. Toglia JU. Is migraine due to a deficiency of pineal melatonin? Ital J Neurol Sci. 1986 Jun;7(3):319-23.

43. Claustrat B, Loisy C, Brun J, Beorchia S, Arnaud JL, Chazot G. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache. 1989 Apr;29(4):242-5.

44. Claustrat B, Brun J, Geoffriau M, Zaidan R, Mallo C, Chazot G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia. 1997 Jun;17(4):511-7.

45. Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. Altern Med Rev. 2001 Aug;6(4):383- 9.

46. Lerchl A. Increased oxidation of pineal serotonin as a possible explanation for reduced melatonin synthesis in the aging Djungarian hamster (Phodopus sungorus). Neurosci Lett. 1994 Jul 18;176(1):25-8.

47. Rozencwaig R, Grad BR, Ochoa J. The role of melatonin and serotonin in aging. Med Hypotheses. 1987 Aug;23(4):337-52.

48. Maurizi CP. Disorder of the pineal gland associated with depression, peptic ulcers, and sexual dysfunction. South Med J. 1984 Dec;77(12):1516-8.

49. Gelmers HJ. Calcium-channel blockers in the treatment of migraine. Am J Cardiol. 1985 Jan 25;55(3):139B-43B.

50. Welch KM. Pathogenesis of migraine. Semin Neurol. 1997;17(4):335-41.

51. Silberstein SD. Sex hormones and headache. Rev Neurol (Paris). 2000; 156 (Suppl 4):4S30- 41.

52. Silberstein SD. The role of sex hormones in headache. Neurology. 1992 Mar;42(3 Suppl 2):37-42.

53. Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology. 1991 Jun;41(6):786-93.

54. Murialdo G, Martignoni E, De Maria A, et al. Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine. Cephalalgia. 1986 Mar;6(1):43- 9.

55. Beckham JC, Krug LM, Penzien DB, et al. The relationship of ovarian steroids, headache activity and menstrual distress: a pilot study with female migraineurs. Headache. 1992 Jun;32(6):292-7.

56. Holdaway IM, Parr CE, France J. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex. Aust N Z J Obstet Gynaecol. 1991 May;31(2):164-5.

57. Sarrel PM. Ovarian hormones and the cir- culation. Maturitas. 1990 Sep;12(3):287-98.

58. Horowski R, Runge I. Possible role of gonadal hormones as triggering factors in migraine. Funct Neurol. 1986 Oct;1(4):405- 14.

59. Sarrel PM. The differential effects of oestrogens and progestins on vascular tone. Hum Reprod Update. 1999 May;5(3):205-9.

60. Massiou H. Female hormones and migraine. Pathol Biol (Paris). 2000 Sep;48(7):672-8.

61. Damasio H, Corbett JJ. Estrogens and migraine. Ann Neurol. 1981 Jan;9(1):92.

62. Magos AL, Zilkha KJ, Studd JW. Treatment of menstrual migraine by oestradiol implants. J Neurol Neurosurg Psychiatry. 1983 Nov;46(11):1044-6.

63. Thys-Jacobs S. Micronutrients and the pre-menstrual syndrome: the case for calcium. J Am Coll Nutr. 2000 Apr;19(2):220-7.

64. Aloisi P, Marrelli A, Porto C, Tozzi E, Cerone G. Visual evoked potentials and serum magnesium levels in juvenile migraine patients. Headache. 1997 Jun;37(6):383-5.

65. Li W, Zheng T, Altura BM, Altura BT. Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascu- lar smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. Brain Res Bull. 2001 Jan 1;54(1):83-9.

66. Facchinetti F, Nappi G, Cicoli C, et al. Reduced testosterone levels in cluster headache: a stress-related phenomenon? Cephalalgia. 1986 Mar;6(1):29-34.

67. Waldenlind E, Gustafsson SA. Prolactin in cluster headache: diurnal secretion, response to thyrotropin-releasing hormone, and relation to sex steroids and gonadotropins. Cephalalgia. 1987 Mar;7(1):43-54.

68. Romiti A, Martelletti P, Gallo MF, Giacovazzo M. Low plasma testosterone levels in cluster headache. Cephalalgia. 1983 Mar;3(1):41-4.

69. Epstein MT, Hockaday JM, Hockaday TD. Migraine and reproductive hormones throughout the menstrual cycle. Lancet. 1975 Mar 8;1(7906):543-8.

70. Mattsson P. Serum levels of androgens and migraine in postmenopausal women. Clin Sci (Lond). 2002 Nov;103(5):487-91.

71. Kudrow L. Changes of testosterone levels in the cluster headache syndrome. Preliminary study. Minerva Med. 1976 Jun 2;67(28):1850- 3.

72. Dzugan SA, Smith RA. The simultaneous restoration of neurohormonal and metabolic integrity as a very promising method of migraine management. Bull Urg Rec Med. 2003;4(4):622-8.

73. Sheftell FD, Atlas SJ. Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. Headache. 2002 Oct;42(9):934-44.

74. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003 Apr 22;60(8):1308-12.

75. Bourgault P, Gratton F. Help-seeking behavior of women with migraines. Rech Soins Infirm. 2001 Jun;(65):83-92.

76. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol. 1996;398:373-9.

77. Peres MF. Fibromyalgia, fatigue, and headache disorders. Curr Neurol Neurosci Rep. 2003 Mar;3(2):97-103.

78. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs. 2002;16(11):731-43.

79. Diamond S, Wenzel R. Practical approaches to migraine management. CNS Drugs. 2002;16(6):385-403.